Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-07-13
2010-02-16
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C436S517000
Reexamination Certificate
active
07662571
ABSTRACT:
Damage to tissue, such as ischemic damage, can cause the release of mitochondrial proteins. The released proteins can be detected in a sample taken from a subject, indicating that the subject has suffered damage.
REFERENCES:
patent: 5091404 (1992-02-01), Elgebaly
patent: 5270163 (1993-12-01), Gold et al.
patent: 5403914 (1995-04-01), Elgebaly
patent: 5504013 (1996-04-01), Senior
patent: 5606027 (1997-02-01), Elgebaly
patent: 5622871 (1997-04-01), May et al.
patent: 6235241 (2001-05-01), Catt et al.
patent: 6399398 (2002-06-01), Cunningham et al.
patent: 6670138 (2003-12-01), Gonzalez-Zulueta et al.
patent: 2005/0137481 (2005-06-01), Sheard et al.
patent: WO 91/19813 (1991-12-01), None
patent: WO 92/05285 (1992-04-01), None
patent: WO 92/14843 (1992-09-01), None
patent: WO 03/074069 (2003-09-01), None
Lutsenko et al. Proc. Natl. Acad. Sci. 1998 vol. 95, p. 6004-6009.
Koehler et al. Proc. Natl. Acad. Sci. 1999 vol. 96. page 2141-2146.
Burgess et al (J Cell Biol. 111:2129-2138, 1990).
Beattie M.S., Trends in Molecular Medicine, 2004, vol. 19, No. 12, pp. 580-583.
Yamazaki et al., European Journal of Pharmacology, 2001, vol. 413, pp. 173-178.
O'Flaherthy et al., The Journal of Immunology, 1978, vol. 120, No. 4, pp. 1326-1332.
Le et al., Trends in Immunology, 2002, vol. 23, No. 11, pp. 541-548.
Alpert, J.S. et al., “Myocardial Infarction Redefined—A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction,” J. Am. Coll. Cardiol. 2000; 36; 959-69.
Boersma, E. et al., “Platelet glycoprotein IIb/IIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials,” Lancet 2002:359: 189-98.
Brennan, M.L. et al., “Prognostic Value of Myeloperoxidases in Patients with Chest Pain,” N. Engl. J. Med. 2003: 349:1595-604.
Christenson, R.H. et al., “Characteristics of an Albumin Cobalt Binding Test for Assessment of Acute Coronary Syndrome Patients: A Multicenter Study,” Clin. Chem. 2001; 47:464-470.
Christenson, R.H. And Azzazy, H.M.E., “Biochemical markers of acute coronary syndromes,” Clin. Chem., 44, 1855-64, 1998.
Danne, O. et al., “Prognostic Implications of Elevated Whole Blood Choline Levels in Acute Coronary Syndrome,” Am. J. Cardiol. 2003; 91: 1060-7.
de Lemos, J.A. et al., “The Prognostic Value of Serum Myoglobin in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes,” J. Am. Coll. Cardiol. 2002; 40: 238-44.
Doherty, D.E. et al., “Human Monocyte Adherence: A Primary Effect of Chemotactic Factors on the Monocyte to Stimulate Adherence to Human Endothelium,” J. Immunol. 138(6), 1762-1771, 1987.
Elgebaly, S.A. et al., “Cardiac Derived Neutrophil Chemotactic Factors; Preliminary Biochemical Characterization,” J. Mol. Cell Cardiol., 21:585-593, 1989.
Elgebaly, S.A. et al., “Cyclocreatine Inhibits the Production of Nutrophil Chemotactic Factors from Isolated hearts,” Am. J. Pathol. 137: 1233-1241, 1990.
Elgebaly, S.A. et al., “Cardiac-derived neutophil chemotactic factors: Detection in coronary sinus effluents of patients undergoing myocardial revascularization,” J. Thorac. Cardiovasc. Surg., 130(5): 952-959, 1992.
Elgebaly, S.A. et al., “Evidence of Cardiac Inflammation After Open Heart Operations,” Ann. Thorac. Surg., 57:391-396, 1994.
Joyce, “Amplification, mutation and selection of catalytic RNA” (1980) Gene 82:83-87.
Kleinfeld, A.M. et al., “Increases in Serum Unbound Free Fatty Acid Levels Following Coronary Angioplasty,” Am. J. Cardiol., 1996, 78:1350-4.
Lucchesi, B.R. et al., “Leukocytes and Ischemia-induced Myocardial Injury,” Annu. Rev. Pharmacol. Toxicol., 26: 201-224, 1986.
Newby, L.K. et al., “Bedside Multimarker Testing fr Risk Stratification in Chest Pain Units,” Circulation, 2001, 103:1832-7.
Szostak et al., “In vitro selection of RNA molecules that bind specific ligands,” (1990) Nature 346:818-822.
Tuerk et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polylmerase” (1990) Science 249:505-510.
Yamamoto, Yuri et al., “Inhibitory Effects of Spinorphin, a Novel Endogenous Regulator, on Chemotaxis, O2 Generation, and Exocytosis by N-Formylmethionyl-leucyl-phenylalanine (FMLP)-Stimulated Neutrophils,” Biochemical. Pharmacology, 54; 695-701, 1997.
Trueba et al. (J. Bacteriology 1992 vol. 174, p. 4761-4768.
Elgebaly Salwa A.
Schiffmann Elliott
Cheu Jacob
Latimer & Mayberry IP Law LLP
Nourheart Inc.
LandOfFree
Mitochondrial markers of ischemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mitochondrial markers of ischemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitochondrial markers of ischemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179474